SERA (Sera Prognostics) Gross Margin %: -200.00% (As of Mar. 2026)


SERA Sera Prognostics Inc SERA
70 GF Score
Price $1.84
GF Value $1.86
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Sera Prognostics Gross Margin %?

Sera Prognostics SERA -2.17% 70 Gross Margin % is -200.00% as of Mar. 2026. GuruFocus rates SERA with a GF Score™ of 70/100 and a GF Value™ of $1.86 (Fairly Valued). The stock has 5 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Sera Prognostics ranks worse than 98.39% on this metric.

Gross Margin % is calculated as gross profit divided by its revenue. Sera Prognostics's Gross Profit for the three months ended in Mar. 2026 was $-0.03 Mil. Sera Prognostics's Revenue for the three months ended in Mar. 2026 was $0.01 Mil. Therefore, Sera Prognostics's Gross Margin % for the quarter that ended in Mar. 2026 was -200.00%.


The historical rank and industry rank for Sera Prognostics's Gross Margin % or its related term are showing as below:

SERA' s Gross Margin % Range Over the Past 10 Years
Min: -191.23   Med: 31.37   Max: 56
Current: -191.23


During the past 7 years, the highest Gross Margin % of Sera Prognostics was 56.00%. The lowest was -191.23%. And the median was 31.37%.

SERA's Gross Margin % is ranked worse than
98.39% of 805 companies
in the Medical Devices & Instruments industry
Industry Median: 52.07 vs SERA: -191.23

Sera Prognostics had a gross margin of -200.00% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Sera Prognostics was 0.00% per year.


Sera Prognostics  (NAS:SERA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Sera Prognostics had a gross margin of -200.00% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Sera Prognostics Gross Margin % Related Terms


Sera Prognostics Gross Margin % Historical Data

* Premium members only.

The historical data trend for Sera Prognostics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sera Prognostics Gross Margin % Chart

Sera Prognostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Gross Margin %
Get a 7-Day Free Trial 54.88 27.99 31.37 -6.49 -102.47

Sera Prognostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.26 -141.18 -156.25 -320.00 -200.00

SERA vs ECOR, OM, RTGN: Gross Margin % Comparison

For the Medical Devices subindustry, Sera Prognostics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sera Prognostics Gross Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Sera Prognostics's Gross Margin % falls into.


SERA
70GF Score
Sera Prognostics Inc SERA
Gross Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sera Prognostics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Sera Prognostics's Gross Margin for the fiscal year that ended in Dec. 2025 is calculated as

Gross Margin % (A: Dec. 2025 )=Gross Profit (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-0.1 / 0.081
=(Revenue - Cost of Goods Sold) / Revenue
=(0.081 - 0.164) / 0.081
=-102.47 %

Sera Prognostics's Gross Margin for the quarter that ended in Mar. 2026 is calculated as


Gross Margin % (Q: Mar. 2026 )=Gross Profit (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-0 / 0.014
=(Revenue - Cost of Goods Sold) / Revenue
=(0.014 - 0.042) / 0.014
=-200.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Margin % →
What does a Gross Margin % of -200.00% mean?
Sera Prognostics (SERA) has a Gross Margin % of -200.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Sera Prognostics and its competitors. According to the industry distribution chart, Sera Prognostics ranks #792 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 98.4%.
Is Sera Prognostics' Gross Margin % too high?
Sera Prognostics' current Gross Margin % is -200.00%. Based on the distribution chart, Sera Prognostics ranks #792 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sera Prognostics has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' Gross Margin % compare to ECOR and OM?
According to the Medical Devices & Instruments industry distribution chart, Sera Prognostics ranks #792 out of 805 companies for Gross Margin %. This places Sera Prognostics in the lower half of its industry. The industry median Gross Margin % is 52.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sera Prognostics and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sera Prognostics's current Gross Margin % is -200.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Fairly Valued. The stock's GF Value™ is $1.86, compared to a current price of $1.84 — trading 1.1% below its estimated fair value. The current Gross Margin % is -200.00%. Sera Prognostics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sera Prognostics (SERA), the current Gross Margin % is -200.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sera Prognostics (SERA) Overvalued in 2026?

Based on GuruFocus' analysis, Sera Prognostics stock appears to be undervalued. The current stock price of $1.84 is trading 1.1% below its estimated GF Value™ of $1.86. GuruFocus considers Sera Prognostics to be Fairly Valued.

Key valuation signals for SERA:

  • Gross Margin %: -200.00%
  • GF Value™: $1.86 vs. price of $1.84 (1.1% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sera Prognostics Business Description

Address 2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
70GF Score

Get the complete analysis for SERA

Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.84
Price
$1.86
GF Value